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Abstract: At the Trauma, Shock, Inflammation
and Sepsis 2007 conference, the roles of comple-
ment activation products and relevant receptors
were stressed in the setting of experimental sepsis
[cecal ligation and puncture (CLP)] in mice and
rats. In addition, some limited evidence was pre-
sented related to humans with septic shock (requir-
ing vasopressor support). Collectively, the data
suggested that events found in CLP also occur in
human sepsis. Experimental sepsis (CLP) in ro-
dents is associated with robust complement con-
sumption and appearance of activation products
(C3a, C5a) in plasma. During sepsis, there is up-
regulation of C5a receptors (C5aR, C5L2) on
blood polymorphonuclear neutrophils (PMNs) and
in lungs, liver, kidneys, and heart. CLP also leads
to dramatic reductions of C5aRs on blood PMNs,
the intensity of which correlates with lethality. In-
terception in vivo of C5a or C5aR dramatically
improves survival after CLP, preserves innate im-
mune functions of blood PMNs, and greatly atten-
uates the intensity of consumptive coagulopathy
and activation of the fibrinolytic system after CLP.
In humans with septic shock, there is evidence of
complement activation products in plasma along
with loss of C5aRs on blood PMNs. These data
suggest that in septic humans, interception of C5a
or C5aR might be clinically efficacious. J. Leukoc.
Biol. 83: 467–470; 2008.
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INTRODUCTION
It is well known that humans with sepsis have evidence of
systemic activation of complement, as demonstrated by the
presence in plasma/serum of complement activation products
(C3a, C5a, C5b-9) [1]. The complement anaphylatoxins, C3a
and C5a, are known to have a spectrum of proinflammatory
activities [2], suggesting that systematic formation of C3a and
C5a is highly undesirable, as these complement products can
function at low nM concentrations and are intensely proinflam-
matory. Plasma contains carboxypeptidases, which rapidly
convert C3a and C5a to des arg forms, that are less biologically
reactive. However, the situation is confused by the fact that
plasma complement proteins, which originate predominately
from hepatocytes, can also be synthesized locally {in the rel-
ative absence of carboxypeptidases, as in lung (reviewed in
refs. [3, 4]}. In addition, phagocytic cells, such as neutrophils
and tissue macrophages, contain a C5 convertase, which can
generate C5a from C5 in the absence of other complement
proteins [4]. In addition, thrombin can generate C5a from C5
[5], indicating a linkage between the coagulation and comple-
ment systems [5].
THE C5a RECEPTOR (C5aR) AND ROLE
IN SEPSIS
The C5aR (CD88) is described in Table 1. C5aR is a 7
transmembrane-spanning receptor, which binds C5a (and C5a
des arg) with high affinity (low nM range), and is linked with
intracellular G proteins, necessary for cellular signaling. In-
teraction of C5aR with C5a results in a rapid increase in
cytosolic Ca2 as a result of release of Ca2 from intracellular
stores. The cytosolic Ca2 increase is transient but is one of the
earliest responses of cells to C5a. Although it used to be
thought that the C5aR presence was restricted to myelopoietic
cells, it is now clear that C5aR is expressed on a variety of
other cell types, such as endothelial cells, alveolar epithelial
cells, neurons, and cardiomyocytes (CMs), to name just a few
examples. The expression of C5aR is constitutive and induc-
ible. In the setting of experimental sepsis induced by cecal
ligation and puncture (CLP), C5aR is up-regulated substan-
tially in a variety of organs [6]. In thymocytes, up-regulation
occurs within a few hours after CLP [7]. Up-regulation of C5aR
after CLP has also been found on CMs [8], as well as in liver,
lung, and kidney [6]. Such up-regulation infers that a variety of
tissues may develop highly undesirable effects after encounters
with C5a. In the heart, profound CM contractile defects de-
velop after CLP [8]. In the thymus and perhaps in other
lymphoid tissues, apoptosis develops, via the intrinsic pathway
(featuring mitochondrial release of cytochrome c and caspase
activation) [9]. Apoptosis is known to occur in lymphoid tissues
of septic humans and has been postulated to be the cause of the
immunosuppression of sepsis [10].
In vitro, it is known that C5aR can be up-regulated by cell
contact with LPS, TNF-, or IL-6. In vivo, blockade of IL-6
prevents up-regulation of C5aR in CLP rodents and improves
survival [11]. In the setting of CLP, organ up-regulation of
C5aR can be blocked in mice by administration of neutralizing
antibody to IL-6 [2]. Finally, interaction of C5a with C5aR on
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blood polymorphonuclear neutrophils (PMNs) results in inter-
nalization of the C5a•C5aR complex, with translocation to the
Golgi region, where in an acidic environment, the ligand (C5a)
is hydrolyzed, and at least some of the C5aR is recycled to the
cell membrane. In CLP rats, the greater the loss of C5aR on the
PMN surfaces, the higher the lethality [12]. This relationship
may reflect the intensity of in vivo complement activation
during sepsis or the ability of PMNs to replete C5aR rapidly on
cell surfaces. Currently, there are ongoing studies in human
sepsis to determine if the loss of C5aR on PMNs is predictive
of a lethal outcome.
THE C5L2R FOR C5a AND CHANGES
IN SEPSIS
The recently described second C5aR on leukocytes, C5L2, is
rather enigmatic [13–18]. C5L2 was described several years
ago [13–18]. C5L2 is reviewed in Table 2. It was quickly
determined that, although C5L2 binds C5a and C5a des arg
with high affinity, no intracellular Ca2 signal developed, and
no functional response occurred (e.g., enzyme release, respi-
ratory burst, MAPK signaling, etc.). Accordingly, C5L2 was
judged to be a default or “scavenger” receptor, in which it
would bind C5a and compete with C5aR for C5a binding.
Although it has been suggested that C5L2 is a “promiscuous”
receptor, which can also bind C3a and C3a des arg on myeloid
cells and adipocytes, such claims have been questioned re-
cently [15]. Although no cell signaling was thought to occur
upon engagement of C5L2, this matter has been confused in
light of two recent reports, which suggest signaling in adipo-
cytes exposed to C3a or C3a des arg [16] and mouse bone
marrow-derived phagocytes incubated with C5a [18]. In the
case of bone marrow-derived macrophages, it has been sug-
gested that in the absence of C5aR or C5L2, ERK1/2 phos-
phorylation is diminished. It is difficult to reconcile these
contrasting claims at the present time.
In vivo experiments suggest that C5L2 may alter the balance
of the inflammatory response. When C5L2 was blocked in CLP
mice, there was a dramatic increase in serum IL-6, whereas
blockade of C5aR with antibody had the opposite effect, vir-
tually abolishing serum IL-6 after CLP [19]. When IgG im-
mune complex-induced injury was evaluated, the intensity of
lung injury was amplified in C5L2/ mice compared with
wild-type mice [20]. These in vivo observations suggest that
C5L2 functions to negatively regulate the level of the inflam-
matory response in vivo, but it is clear that there is inadequate
information to be certain about the function of C5L2. Finally,
studies to date suggest that C5a ligation of C5L2 does not result
in internalization of the receptor, which remains on the cell
surface. It is possible that this could be explained by the
inability of C5a to initiate cell signaling via C5L2. Evidence for
changes in C5L2 in the setting of CLP-induced sepsis or in
human sepsis is described below.
EVIDENCE FOR THE ROLE OF C5a IN
EXPERIMENTAL SEPSIS
The data described in Table 3 are the foundations for con-
cluding that in CLP rodents, the septic syndrome is linked to
generation of C5a. As in humans with sepsis, complement
activation after CLP is associated with consumptive depletion
of complement and the appearance in plasma/serum of C5a
[21]. When C5a was blocked in vivo (at the time of CLP), there
was a dramatic improvement in survival [21, 22]. Paralysis of
the ERK1/2 signaling pathway was found in blood PMNs
within 12–18 h after CLP [23], resulting in marked defects in
phagocytosis, chemotaxis, and assembly of NADPH oxidase.
These functional defects in PMNs were prevented when C5a
was intercepted with anti-C5a immediately after CLP. Similar
restrictions in innate immune responses were found in human
blood PMNs exposed in vitro to C5a. The basis for the defect
in the respiratory burst was the inability of stimulated PMNs to
translocate one of the critical subunits (p47phox) from the
cytosol to the cell membrane, where assembly of NADPH
oxidase occurs.
When C5a was blocked in CLP rats, this also resulted in
preservation of CM contractility as measured in vitro, sharply
contrasting with the 50–60% loss of contractility when CLP
TABLE 3. Role of C5a in CLP-Induced Sepsis
1. Increased C5a levels in plasma after CLP.
2. Protective effects of C5a blockade.
3. Ability of C5a in vitro and in vivo to induce signaling paralysis
of ERK1/2 signaling.
4. Ability of C5a blockade in vivo to preserve contractility of
cardiomyocytes.
5. Ability of C5a to cause defective cardiomyocyte contractility in
vitro.
6. Ability of anti-C5a to attenuate the consumptive coagulopathy
of experimental sepsis.
TABLE 1. C5aR
1. 7 Transmembrane-spanning receptor.
2. Linked with cytosolic G-protein signaling.
3. Specifically reactive with C5a and C5a des arg.
4. Present on phagocytic cells as well as nonmyelopoietic cells
(endothelial cells, Kupfer cells, alveolar epithelial cells, etc.).
5. C5aR is inducible by LPS, IL-6, TNF-.
6. Facilitates a variety of functional responses (intracellular Ca2
signaling, secretory granule release, activation of NADPH
oxidase, etc.).
7. C5a binding to C5aR induces intracellular translocation and
subsequent recycling of C5aR.
TABLE 2. C5L2
1. 7 Transmembrane-spanning receptor which is not linked to
G-protein signaling because of a substitution in the Asp-Arg-
Tyr (DRY) region.
2. Reaction with C5a and C5a des arg; questionable binding of
C3a and C3a des arg.
3. A “default” receptor.
4. Present on a variety of myelopoietic and nonmyelopoietic cells.
5. Inducible on a variety of cells.
6. Ligation of C5L2 does not appear to result in internalization.
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rodents were treated with preimmune serum at the time of CLP
[8]. It was also shown that addition of C5a in vitro to sham CMs
in a dose-dependent manner caused progressive reductions in
CM contractility. This could be explained by the constitutive
presence of C5aR on CMs. Finally, in CLP rats, the expected
evidence of consumptive coagulopathy was demonstrated
readily together with evidence for activation of the fibrinolytic
system. All such abnormalities were greatly attenuated when
C5a blockade was initiated at the start of CLP [24]. Thus, the
abnormalities developing in the innate immune pathways dur-
ing experimental sepsis in CMs and in the clotting/coagulation
systems are linked to the generation of C5a after CLP.
ROLE FOR C5aR IN EXPERIMENTAL SEPSIS
As indicated above, C5aR is up-regulated after CLP in rats and
in mice. There is considerable evidence for the participation of
C5aR in the harmful consequences of experimental sepsis.
Blockade of C5aR has been accomplished by the use of anti-
body to C5aR or by the use of a cyclic peptide, which prevents
interaction of C5a with C5aR [25]. In vivo blockade of C5aR
resulted in greatly improved survival after sepsis. In addition,
interception of IL-6 (which is a potent inducer of C5aR)
significantly improved survival after CLP in mice [11]. Collec-
tively, these data provide direct evidence for the harmful role
of C5aR in the setting of experimental sepsis. The harmful
effects of C5a interaction with C5aR in the setting of experi-
mental sepsis are described in Figure 1, in which sepsis-
induced activation of complement results in two harmful out-
comes: loss of innate immune functions of blood neutrophils
(PMNs) and reduced CM contractility. The appearance of both
types of defects is C5a- and C5aR-dependent. In the case of
PMNs, signaling paralysis results in loss of three key functions
(phagocytosis, chemotaxis, assembly of NADPH oxidase), all of
which results in the loss of protective functions of PMNs. In the
case of CM, sepsis results in increased cell surface expression
of C5aR. Upon interaction with C5a, CM contractility is re-
duced greatly, resulting in falling left ventricular pressures and
reduced cardiac output. Development of these dysfunctions
can be blocked by in vivo interception (with antibody) of C5a.
CLINICAL CORRELATES IN HUMAN SEPSIS
There is developing evidence that humans with septic shock
(requiring vasopressors to maintain adequate blood pressure)
show several of the features observed in septic rodents after
CLP. In both situations, there is evidence of consumptive
depletion of complement in serum/plasma and the presence of
complement activation products (C3a, C5a). Another set of
observations relates to C5L2 content on blood PMN lysates
(defined by Western blots) and on blood PMNs (as determined
by flow cytometric analysis) from humans with septic shock. In
the case of rats, lysates from blood PMNs, 24 h after CLP,
showed a dramatic reduction in C5L2 content, as defined by
Western blot analysis [26]. The loss of C5L2 occurred as a
function of time after CLP, and substantial reductions occurred
at 3 h and 4 h. In addition, it was shown that the loss of PMN
C5L2 after CLP was dependent on C5a, as in vivo blockade of
C5a prevented the loss of C5L2 from blood PMNs. In the case
of humans with septic shock, C5L2 levels fell 95% on PMNs
in the aggregate group of septic patients, by 84% in septic
patients without multiorgan failure (MOF), and by nearly 90%
in septic patients with MOF. The loss of C5L2 on normal
human PMNs could be reproduced when cells were exposed in
vitro to C5a, indicating a loss of receptor by internalization or
by receptor shedding. These data indicate that sepsis causes
dramatic reductions in PMN surface content of C5L2 and that
the same occurs on blood PMNs taken from CLP rats. The loss
of C5L2 has been shown to be C5a-dependent. To what extent
similar changes occur in C5aR in blood PMNs in septic hu-
mans is a matter of current study.
SUMMARY
There is accumulating evidence that complement activation
occurs during experimental sepsis (CLP) and also in human
sepsis. Interaction of the anaphylatoxin, C5a, with its receptor,
C5aR, has highly adverse consequences. When C5a interacts
with blood PMNs, signaling pathways are paralyzed, associated
with internalization of C5a-C5aRs complexes. Signaling paral-
ysis results in loss of innate immune functions of PMNs (phago-
cytosis, chemotaxis, assembly of NADPH oxidase), which has
ominous implications for defenses against bacteremia. With
respect to the well-known cardiomyopathy of sepsis, the loss of
cardiac function can be linked to C5a interaction with C5aR on
CMs. In vivo interception of C5a or C5aR is highly protective
in the setting of experimental sepsis, greatly improving survival
after CLP, preserving the innate immune functions of PMNs,
and normalizing cardiac function. The data suggest that in vivo
Fig. 1. Summary of C5a-C5aR interactions in sepsis, leading to loss of innate
immune functions of PMNs and contractile dysfunction of CMs.
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blockade of C5a or C5aR may be protective in the setting of
sepsis in humans.
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